Pencho G. Georgiev

Plovdiv, Bulgaria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Analysis of the antitrypsin activity and immunoglobulin G concentration in equine colostrum and milk.

Analysis of the antitrypsin activity and immunoglobulin G concentration in equine colostrum and milk.

Journal: Journal of equine veterinary science

Published: May 04, 2025

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Journal: HemaSphere

Published: January 28, 2025

Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.

Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial.

Journal: The Lancet. Haematology

Published: August 21, 2024

Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.

Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.

Journal: Blood advances

Published: June 07, 2024

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Journal: Leukemia

Published: May 15, 2023

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Journal: Leukemia

Published: December 25, 2021

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Journal: HemaSphere

Published: April 14, 2020

Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia.

Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia.

Journal: Annals of medicine

Published: March 28, 2020

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

Journal: The New England journal of medicine

Published: March 27, 2020

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Journal: Journal of thrombosis and haemostasis : JTH

Published: March 24, 2020

Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.

Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities.

Journal: Folia medica

Published: August 28, 2019

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Journal: The Lancet. Haematology

Published: July 23, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026